An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

Cellular and Molecular Life Sciences

Volumn 55, Issue 6-7, 1999, Pages 932-943

  Gelman, L ^a   Fruchart, J C ^a   Auwerx, J ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Cofactor; Inflammation; Lipid homeostasis; Nuclear receptor; PPAR; Tumorigenesis apoptosis

Indexed keywords

CELL NUCLEUS RECEPTOR; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; GENE CONTROL; GENE EXPRESSION; HOMEOSTASIS; HUMAN; INFLAMMATION; LIPID METABOLISM; NUTRITION; PEROXISOME; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033049772     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050345     Document Type: Review

References (142)

1. 1 Kliewer S. A., Umesono K., Noonan D. J., Heyman R. A. and Evans R. M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774
2. 2 Schoonjans K., Martin G., Staels B. and Auwerx J. (1997) Peroxisome proliferator-activated receptor, orphans with ligands and functions. Curr. Opin. Lipidol. 8: 159-166
3. 3 Schoonjans K., Staels B. and Auwerx J. (1996) The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302: 93-109
4. 4 Issemann I. and Green S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650
5. 5 Lee S. S., Pineau T., Drago J., Lee E. J., Owens J. W., Kroetz D. L. et al. (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 15: 3012-3022
6. 6 Braissant O., Foufelle F., Scotto C., Dauca M. and Wahli W. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta and -gamma in the adult rat. Endocrinology 137: 354-366
7. 7 Schoonjans K., Staels B. and Auwerx J. (1996) Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925
8. 8 Devchand P. R., Keller H., Peters J. M., Vazquez M., Gonzalez F. J. and Wahli W. (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384: 39-43
9. 9 Forman B. M., Chen J. and Evans R. M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA 94: 4312-4317
10. 10 Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wiseley G. B., Koble C. S. et al. (1997) Fatty acids and eicosamoids regulate gene expression through direct iteractions with peroxysome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA 94: 4318-4323
11. 11 Tontonoz P., Hu E., Graves R. A., Budavari A. I. and Spiegelman B. M. (1994) mPPARgamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8: 1224-1234
12. 12 Tontonoz P., Hu E. and Spiegelman B. M. (1994) Stimulation of adipogenesis in fibroblasts by PPARgamma2, a lipid-activated transcription factor. Cell 79: 1147-1156
13. 13 Hu E., Tontonoz P. and Spiegelman B. M. (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARgamma and C/EBPalpha. Proc. Natl. Acad. Sci. USA 92: 9856-9860
14. 14 Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.-M., Saladin R. et al. (1997) The human PPARgamma gene: organization, promoter analysis and expression. J. Biol. Chem. 272: 18779-18789
15. 15 Zhu Y., Qi C. and Korenberg J. R. (1995) Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPARgamma) gene: alternative promoter use and different splicing yield two mPPARgamma isoforms. Proc. Natl. Acad. Sci. USA 92: 7921-7925
16. 16 Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J. et al. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 95: 7614-7619
17. 17 Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.-P. et al. (1997) Tissue distribution and quantification of the expression of PPARs and of LXRalpha in human: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 48: 1319-1327
18. 18 Gustafsson J. A. (1998) Fatty acids in control of gene expression. Nutr. Rev. 56: s20-1; discussion s54-75
19. 19 Spiegelman B. M. and Flier J. S. (1996) Adipogenesis and obesity: rounding out the big picture. Cell 67: 377-389
20. 20 Willson T. M. and Wahli W. (1997) Peroxisome proliferator-activated receptor agonists. Curr. Opin. Chem. Biol. 1: 235-241
21. 21 Schoonjans K., Peinado-Onsurbe J., Lefebvre A. M., Heyman R. A., Briggs M., Deeb S. et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348
22. 22 Schoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W. et al. (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270: 19269-19276
23. 23 Schoonjans K., Staels B., Grimaldi P. and Auwerx J. (1993) Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur. J. Biochem. 216: 615-622
24. 24 Martin G., Schoonjans K., Lefebvre A.-M., Staels B. and Auwerx J. (1997) Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 272: 28210-28217
25. 25 Motojima K., Passilly P., Peters J. M., Gonzalez F. J. and Latruffe N. (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273: 16710-16714
26. 26 Tontonoz P., Hu E., Devine J., Beale E. G. and Spiegelman B. M. (1995) PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell Biol. 15: 351-357
27. 27 Auwerx J., Martin G., Guerre-Millo G. and Staels B. (1996) Transcription, adipocyte differentiation and obesity. J. Mol. Med. 74: 347-352
28. 28 De Vos P., Lefebvre A.-M. and Miller S. G. (1996) Thiazolidinediones repress ob gene expression via activation of PPARgamma. J. Clin. Invest. 98: 1004-1009
29. 29 Hollenberg A. N., Susulic V. S. and Madura J. P. (1997) Functional antagonism between CCAAT, enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma on the leptin promoter. J. Biol. Chem. 272: 5283-5290
30. 30 Kallen C. B. and Lazar M. A. (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA 93: 5793-5796
31. 31 Zhang B., Graziano M. P. and Doebber T. W. (1996) Down-regulation of the expression of the obese gene by antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db-db mice. J. Biol. Chem. 271: 9455-9459
32. 32 Okuno A., Tamemoto H, Tobe K., Ueki K., Mori Y., Iwamoto K. et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese zucker rats. J. Clin. Invest. 101: 1354-1361
33. 33 Hallakou S., Doare L. and Foufelle F. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/a rat. Diabetes 46: 1393-1399
34. 34 Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M. and Evans R. M. (1995) 15-Deoxy-D12,14 prostaglandine J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812
35. 35 Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C. and Lehmann J. M. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813-819
36. 36 Berger J., Bailey P., Biswas C., Cullinan C. A., Doebber T. W., Hayes N. S. et al. (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db db mice. Endocrinology 137: 4189-4195
37. 37 Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. and Kliewer S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 270: 12953-12956
38. 38 Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M. and Kliewer S. A. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272: 3406-3410
39. 39 Hotamisligil G. S., Peraldi P., Budavari A., Ellis R., White M. F. and Spiegelman B. M. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665-668
40. 40 Hotamisligil G. S., Shargill N. S. and Spiegelman B. M. (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91
41. 41 Auwerx J., Bouillon R., Collen D. and Geboers J. (1988) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68-72
42. 42 Cohen B., Novick D. and Rubinstein M. (1996) Modulation of insulin activities by leptin. Science 274: 1185-1188
43. 43 Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T. et al. (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med. 2: 800-803
44. 44 Landin K., Stigendal L., Eriksson E., Krotkiewski M., Risberg B., Tengborn L. et al. (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39: 1044-1048
45. 45 De Vos P., Lefebvre A. M., Miller S. G., Guerre-Millo M., Wong K., Saladin R. et al. (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J. Clin. Invest. 98: 1004-1009
46. 46 Kallen C. B. and Lazar M. A. (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-LI adipocytes. Proc. Natl. Acad. Sci. USA 93: 5793-5796
47. 47 Boden G., Chen X., Ruiz J., White J. V. and Rossetti L. (1994) Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. 93: 2438-2446
48. 48 Randle P. J., Garland P. B., Hales C. N. and Newsholme E. A. (1961) The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 1: 785-789
49. 49 Martin G., Schoonjans K., Staels B. and Auwerx J. (1998) PPAR activators improve glucose homeostasis by changing fatty acid partitioning. 35 47, Proceedings of the XIth International Symposium on Atherosclerosis, Jacotot B., Mathé D., Fruchart J.-C. (eds), Elsevier Science (Singapore).
50. 50 Xing G., Zhang L., Heynen T., Yoshikawa T., Smith M., Weiss S. et al. (1995) Rat PPAR delta contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei. Biochem. Biophys. Res. Commun. 217: 1015-1025
51. 51 Granneman J., Skoff R. and Yang X. (1998) Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J. Neurosci. Res. 51: 563-573
52. 52 Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M. G. et al. (1997) Fatty acids, eicosanoids and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by CARLA. Mol. Endocrinol. 11: 779-791
53. 53 Schmidt A., Vogel R. L., Witherup K. M., Rutledge S. J., Pitzenberger S. M., Adam M. et al. (1996) Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family. Lipids 31: 1115-1124
54. 54 Johnson T. E., Holloway M. K., Vogel R., Rutledge S. J., Perkins J. J., Rodan G. A. et al. (1997) Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. J. Steroid Biochem. Mol. Biol. 63: 1-8
55. 55 Brown P. J., Smith-Oliver T. A., Charifson P, S., Tomkinson N. C., Fivush A. M., Sternbach D. D. et al. (1997) Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chem. Biol. 4: 909-918
56. 56 Wahli W., Braissant O. and Desvergne B. (1995) Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem. Biol. 2: 261-266
57. 57 Brun R. P., Kim J. B., Hu E. and Spiegelman B. M. (1997) Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr. Opin. Lipidol. 8: 212-218
58. 58 Abraham S. E., Lobo S., Yaciuk P., Heidi H.-G. and Moran E. (1993) p300, and p300-associated proteins, are components of the TATA-binding protein (TBP) complexes. Oncogene 8: 1639-1647
59. 59 Nakajima T., Uchida C., Anderson S., Lee C.-G., Hurwitz J., Parvin J. D. et al. (1997) RNA Helicase A mediates association of CBP with RNA polymerase II. Cell 90: 1107-1112
60. 60 Fraser R. A., Rossignol M., Heard D. J., Egly J. M. and Chambon P. (1997) SUG1, a putative transcriptional mediator and subunit of the PA700 proteasome regulatory complex, is a DNA helicase. J. Biol. Chem. 272: 7122-7126
61. 61 Fraser R. A., Heard D. J., Adam S., Lavigne A. C., Le Douarin B., Tora L. et al. (1998) The putative cofactor TIF1alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors. J. Biol. Chem. 273: 16199-16204
62. 62 Bannister A. J. and Kouzarides T. (1996) The CBP co-activator is a histone acyltransferase. Nature 384: 641-643
63. 63 Chen H., Lin R. J., Louis Schiltz L., Chakravarti D., Nash A., Nagy L. et al. (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90: 569-580
64. 64 Korzus E., Torchia J., Rose D. W., Xu L., Kurokawa R., McInerney E. M. et al. (1998) Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279: 703-707
65. 65 Ogryzko V. V., Schiltz R. L., Russanova V., Howard B. H. and Nakatani Y. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959
66. 66 Spencer T. E., Jenster G., Burcin M. M., Allis C. D., Zhou J. and Mizzen C. A. (1997) Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198
67. 67 Martinez-Balbas M. A., Bannister A. J., Martin K., Haus-Seuffert P., Meisterernst M. and Kouzarides T. (1998) The acetyltransferase activity of CBP stimulates transcription. EMBO J. 17: 2886-2893
68. 68 Imhof A., Yang X. J., Ogryzko V. V., Nakatani Y., Wolffe A. P. and Ge H. (1997) Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 7: 689-692
69. 69 Pazin M. J. and Kadonaga J. T. (1997) What's up and down with histone deacetylation and transcription? Cell 89: 325-328
70. 70 Glass C. K., Rose D. W. and Rosenfeld M. G. (1997) Nuclear receptor coactivators. Curr. Opin. Cell. Biol. 9: 222-232
71. 71 Moras D. and Gronemeyer H. (1998) The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10: 384-391
72. 72 DiRenzo J., Söderström M., Kurokawa R., Ogliastro M.-H., Ricote M., Ingrey S. et al. (1997) Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol. Cell. Biol. 17: 2166-2176
73. 73 Dowell P., Ishmael J. E., Avram D., Peterson V. J., Nevrivy D. J. and Leid M. (1997) p300 functions as a coactivator for the peroxysome proliferator-activated receptor alpha. J. Biol. Chem. 272: 33435-33443
74. 74 Lavinsky R. M., Jepsen K., Heinzel T., Torchia J., Mullen T. M., Schiff R. et al. (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N- CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 95: 2920-2925
75. 75 Li H., Gomes P. J. and Don Chen J. (1997) RAC3, a steroid/nuclear receptor receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA 94: 8479-8484
76. 76 Mizukami J. and Taniguchi T. (1997) The antidiabetic agent thiazolidinedione stimulates the interaction between PPARgamma and CBP. Biochem. Biophys. Res. Commun. 240: 61-64
77. 77 Puigserver P., Wu Z., Park C. W., Graves R., Wright M. and Spiegelman B. M. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839
78. 78 Zamir I., Zhang J. and Lazar M. A. (1997) Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev. 11: 835-846
79. 79 Zhu Y., Qi C., Rao M. S. and Reddy J. K. (1997) Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J. Biol. Chem. 272: 25500-25506
80. 80 Zhu Y., Qi C., Calandra C., Sambasiva R. and Janardan K. R. (1996) Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr. 6: 185-195
81. 81 Yuan C. X., Ito M., Fondell J. D., Fu Z. Y. and Roeder R. G. (1998) The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc. Natl. Acad. Sci. USA 95: 7939-7944
82. 82 Rachez C., Suldan Z., Ward J., Chang C. P. B., Burakov D., Erdjument-Bromage H. et al. (1998) A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev. 12: 1787-1800
83. 83 Treuter E., Albrektsen T., Johansson L., Leers J. and Gustafsson J. A. (1998) A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol. 12: 864-881
84. 84 Chrivia J. C., Kwok R. P., Lamb N., Hagiwara M., Montminy M. R. and Goodman R. H. (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855-859
85. 85 Eckner R., Ewen M. E., Newsome D., Gerdes M., DeCaprio J. A., Lawrence J. B. et al. (1994) Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8: 869-884
86. 86 Janknecht R. and Hunter T. (1996) Transcriptional control: versatile molecular glue. Curr. Biol. 6: 951-954
87. 87 Janknecht R. and Hunter T. (1996) A growing coactivator network. Nature 383: 22-23
88. 88 Misiti S., Schomburg L., Yen P. M. and Chin W. W. (1998) Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 139: 2493-2500
89. 89 Chakravarti D., LaMorte V. J., Nelson M. C., Nakajima T., Schulman I. G., Juguilon H. et al. (1996) Role of CBP p300 in nuclear receptor signaling. Nature 383: 99-103
90. 90 Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B. et al. (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403-414
91. 91 Hanstein B., Eckner R, . DiRenzo J., Halachmi S., Liu H., Searey B. et al. (1996) p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA 93: 11540-11545
92. 92 Smith C. L., Oñate S. A., Tsai M.-J. and O'Malley B. W. (1996) CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. USA 93: 8884-8888
93. 93 Kraus W. L. and Kadonaga J. T. (1998) p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev. 12: 331-342
94. 93a Gelman L., Zhou G., Fajas L., Raspé E., Fruchart J.-C., and Auwerx J. (1999) p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent manner respectively. J. Biol. Chem. In press.
95. 94 Oñate S. A., Tsai S. Y., Tsai M.-J. and O'Malley B. W. (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357
96. 95 Takeshita A., Yen P. M., Misiti S., Cardona G. R., Liu Y. and Chin W. W. (1996) Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology 137: 3594-3597
97. 96 Yao T.-P., Ku G., Zhou N., Scully R. and Livingston D. M. (1996) The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl. Acad. Sci. USA 93: 10626-10631
98. 97 Ito M., Yu R. N. and Jameson J. L. (1998) Steroidogenic factor-1 contains a carboxy-terminal transcriptional activation domain that interacts with steroid receptor coactivator-I. Mol. Endocrinol. 12: 290-301
99. 98 Onate S. A., Boonyaratanakornkit V., Spencer T. E., Tsai S. Y., Tsai M. J., Edwards D. P. et al. (1998) The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 273: 12101-12108
100. 99 Na S. Y., Lee S. K., Han S. J., Choi H. S., Im S. Y. and Lee J. W. (1998) Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J. Biol. Chem. 273: 10831-10834
101. 100 Lee S. K., Kim H. J., Na S. Y., Kim T. S., Choi H. S., Im S. Y. et al. (1998) Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J. Biol. Chem. 273: 16651-16654
102. 101 Chen D. J., Umesono K. and Evans R. M. (1996) SMRT isoforms mediate repression and anti-repression of nuclear receptors heterodimers. Proc. Natl. Acad. Sci. USA 93: 7567-7571
103. 102 Chen D. J. and Evans R. M. (1995) A transcriptional corepressor that interacts with nuclear hormone receptors. Nature 377: 454-457
104. 103 Serhan C. N., Haeggstrom J. Z. and Leslie C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10: 1147-1158
105. 104 Zhang B., Berger J., Hu E., Szalkowski D., White-Carrington S., Spiegelman B. M. et al. (1996) Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol. Endocrinol. 10: 1457-1466
106. 105 Williams P. M., Chang D. J., Danesch U., Ringold G. M. and Heller R. A. (1992) CCAAT/enhancer binding protein expression is rapidly extinguished in TA1 adipocyte cells treated with tumor necrosis factor. Mol. Endocrinol. 6: 1135-1141
107. 106 Ron D., Brasier A. R., McGehee R. E. Jr. and Habener J. F. (1992) Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3- L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J. Clin. Invest. 89: 223-233
108. 107 Hill M. R., Young M. D., McCurdy C. M. and Gimble J. M. (1997) Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology 138: 3073-3076
109. 108 Xing H., Northrop J. P., Grove J. R., Kilpatrick K. E., Su J. L., and Ringold G. M. (1997) TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology 138: 2776-2783
110. 109 Peraldi P., Xu M. and Spiegelman B. M. (1997) Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest. 100: 1863-1869
111. 110 Hotamisligil G. S., Murray D. L., Choy L. N. and Spiegelman B. M. (1994) Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA 91: 4854-4858
112. 111 Souza S. C., Yamamoto M. T., Franciosa M. D., Lien P. and Greenberg A. S. (1998) BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 47: 691-695
113. 112 Greene M. E., Blumberg B., McBride O. W., Yi H. F., Kronquist K., Kwan K. et al. (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4: 281-299
114. 113 Tontonoz P., Nagy L., Alvarez J. G., Thomazy V. A. and Evans R. M. (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252
115. 114 Nagy L., Tontonoz P., Alvarez J. G., Chen H. and Evans R. M. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93: 229-240
116. 115 Marx N., Sukhova G., Murphy C., Libby P. and Plutzky J. (1998) Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153: 17-23
117. 116 Spiegelman B. M. (1998) PPARgamma in monocytes: less pain, any gain? Cell 93: 153-155
118. 117 Jiang C., Ting A. T. and Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
119. 118 Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82
120. 119 Colville-Nash P. R., Qureshi S. S., Willis D. and Willoughby D. A. (1998) Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists; correlation with induction of heme oxygenase 1. J. Immunol. 161: 978-984
121. 120 Jedlitschky G., Mayatepek E. and Keppler D. (1993) Peroxisomal leukotriene degradation: biochemical and clinical implications. Adv. Enzyme Regul. 33: 181-194
122. 121 Jedlitschky G., Huber M., Volkl A., Muller M., Leier I., Muller J. et al. (1991) Peroxisomal degradation of leukotrienes by beta-oxidation from the omega-end. J. Biol. Chem. 266: 24763-24772
123. 122 Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P. et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793
124. 123 Iijima K., Yoshizumi M., Ako J., Eto M., Kim S., Hashimoto M. et al. (1998) Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 247: 353-356
125. 124 Bojes H. K., Germolec D. R., Simeonova P., Bruccoleri A., Schoonhoven R., Luster M. I. et al. (1997) Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. Carcinogenesis 18: 669-674
126. 125 Espandiari P., Ludewig G., Glauert H. P. and Robertson L. W. (1998) Activation of hepatic NF-kappaB by the herbicide Dicamba (2-methoxy-3,6-dichlorobenzoic acid) in female and male rats. J. Biochem. Mol. Toxicol. 12: 339-344
127. 126 Rusyn I., Tsukamoto H. and Thurman R. G. (1998) WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. Carcinogenesis 19: 1217-1222
128. 127 Li Y., Leung L. K., Glauert H. P. and Spear B. T. (1996) Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappaB activity. Carcinogenesis 17: 2305-2309
129. 128 Fish oil and blood-vessel wall interactions. (1981) Vanhoutte P. M., Douste-Blazy P. (eds) Editions JL Eurotext, Montrouge
130. 129 Shao D. and Lazar M. A. (1997) Peroxisome proliferator activated receptor gamma, CCAAT enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J. Biol. Chem. 272: 21473-21478
131. 130 Altiok S., Xu M. and Spiegelman B. M. (1997) PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11: 1987-1998
132. 131 Tontonoz P., Singer S., Forman B. M., Sarraf P., Fletcher J. A., Fletcher C. D. et al. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94: 237-241
133. 132 Elstner E., Muller C., Koshizuka K., Williamson E. A., Park D., Asou H, et al. (1998) Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA 95: 8806-8811
134. 133 Mueller E., Sarraf P., Tontonoz P., Evans R. M., Martin K. J., Zhang M. et al. (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1: 465-470
135. 134 Kubota T., Koshizuka K., Williamson E. A., Asou H., Said J. W., Holden S. et al. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58: 3344-3352
136. 135 Lefebvre A.-M. (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/ + mice. Nature Med. 4: 1053-1057
137. 136 Saez E. and Evans R. M. (1998) Activators of the nuclear receptor PPARgamma enhance polyp formation. Nature Med. 4: 1058-1061
138. 137 Anzick S. L., Kononen J., Walker R. L., Azorsa D. O., Tanner M. M., Guan X.-Y. et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968
139. 138 Gariot P., Barrat E., Mejean L., Pointel J. P., Drouin P. and Debry G. (1983) Fenolibrate and human liver. Lack of proliferation of peroxisomes. Arch. Toxicol. 53: 151-163
140. 139 Bayly A. C., Roberts R. A. and Dive C. (1994) Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J. Cell Biol. 125: 197-203
141. 140 Roberts R. A., James N. H., Woodyatt N. J., Macdonald N. and Tugwood J. D. (1998) Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 19: 43-48
142. 141 Aarnisalo P., Palvimo J. J. and Janne O. A. (1998) CREB-binding protein in androgen receptor-mediated signaling. Proc. Natl. Acad. Sci. USA 95: 2122-2127